Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.

You may also be interested in...



Novartis To Launch Exforge In September 2007

Company cannot market the hypertension combination drug until expiration of exclusivity for Pfizer’s Norvasc.

Novartis To Launch Exforge In September 2007

Company cannot market the hypertension combination drug until expiration of exclusivity for Pfizer’s Norvasc.

Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA

Combination of olmesartan and amlodipine can be used alone or in conjunction with other antihypertensives, firm says.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS063390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By